Expert Blog | Beta Cells in Diabetes

Expert BlogBlog RSS

About the Blog

This forum allows a wide variety of leading researchers, endocrinologists, and primary care providers to expand informally on emerging research, case studies, and resources related to beta cells in diabetes, as well providing an opportunity for you to discuss and debate these issues.

Posts by Topic

Posts by Author

Irl B. Hirsch, MD
Endocrinologist

Professor of Medicine, Division of Metabolism, Endocrinology and Nutrition
University of Washington School of Medicine

Read the full biography

Whose Diabetes Treatment Recommendations are Correct?
Posted March 8, 2012 by Irl B. Hirsch, MD

Tags: DPP-4 inhibitors, GLP-1 agonists, glycemic control, insulin therapy, metformin, prediabetes, sulfonylureas (SUs), thiazolidinediones (TZDs)

Primary care physicians are expected to be experts on dozens of different disease states despite the fact that each medical problem continues to evolve, with new understanding of the disease itself and its treatments.
- Continue Reading
- 3 Comments
Diabetes Agents and Carcinogenesis
Posted October 5, 2011 by Irl B. Hirsch, MD

Tags: GLP-1 agonists

It is difficult to forget the dramatic controversy that occurred in the summer of 2009 when four observational studies[1] were published in the journal Diabetologia three of which suggested an association between insulin glargine and certain forms of cancer.
- Continue Reading
- 2 Comments
Challenges in Diabetes Education: Why So Much Confusion?
Posted April 20, 2011 by Irl B. Hirsch, MD

Tags: insulin therapy

While traveling to the American College of Physicians meeting last week in San Diego, I read an interesting article sent to me from the Corpus Christi Caller-Times by Dr. Stephen Ponder.
- Continue Reading
- 3 Comments
New FDA Restrictions And The Future Of TZDs
Posted December 1, 2010 by Irl B. Hirsch, MD

Tags: glycemic control, thiazolidinediones (TZDs), weight

Even after the elimination of troglitazone from the market over ten years ago due to an increased risk of severe liver toxicity, the two remaining thiazolidinediones, rosiglitazone and pioglitazone, have been watched more closely than most new drugs on the market. It was quite clear these agents could result in weight gain, fluid retention, and even pulmonary edema.
- Continue Reading
- 0 Comments
How Do The ACCORD and UKPDS Trials Affect Your T2DM Patients?
Posted September 22, 2010 by Irl B. Hirsch, MD

Tags: glycemic control

A 55-year-old woman with known dyslipidemia and hypertension mentions she has new-onset nocturia for the past three months.
- Continue Reading
- 4 Comments
Treating Beta Cell Dysfunction: The Basic Lesion In T2DM
Posted August 1, 2010 by Irl B. Hirsch, MD

Tags: beta cell pathophysiology

As an endocrinologist at a large diabetes clinic, I see many patients with type 2 diabetes. However, I see very few patients early after their diagnosis--the typical patient seen by most primary care physicians.
- Continue Reading
- 8 Comments

Betacell

A resource for physicians established by the Endocrine Society

Text Size:

Expert BlogBlog RSS

About the Blog

Posts by Topic

Posts by Author

Whose Diabetes Treatment Recommendations are Correct?

Diabetes Agents and Carcinogenesis

Challenges in Diabetes Education: Why So Much Confusion?

New FDA Restrictions And The Future Of TZDs

How Do The ACCORD and UKPDS Trials Affect Your T2DM Patients?

Treating Beta Cell Dysfunction: The Basic Lesion In T2DM